Orris

Suspected case of stroke treatment iv route

Reading File
Finding Sources
Finding Sources
Searching PubMed

"ischemic stroke" AND "intravenous thrombolysis"

Searching the Web

IV tPA alteplase ischemic stroke dosing window contraindications 2024 guideline

Reading File

IV Thrombolysis for Suspected Acute Ischemic Stroke

First step: rule out hemorrhage

Before any thrombolytic is given, a non-contrast CT (or MRI) must exclude intracranial hemorrhage as the cause of the deficit - this is an absolute prerequisite, not optional (Rosen's Emergency Medicine, p. 1435).

Agents and dosing

Alteplase (rt-PA) - the standard, FDA-approved IV thrombolytic for acute ischemic stroke:
  • 0.9 mg/kg IV, maximum total dose 90 mg
  • 10% of the calculated dose given as a bolus over 1 minute, remaining 90% infused over 60 minutes
  • No off-label dose adjustments are recommended (Rosen's Emergency Medicine, p. 1435; also confirmed via USPharmacist review)
Tenecteplase - increasingly used alternative, especially when the patient is also going for mechanical thrombectomy:
  • 0.25 mg/kg IV, maximum 25 mg, given as a single bolus
  • Trial data (EXTEND-IA TNK) show similar or better reperfusion/functional outcome vs alteplase with comparable ICH risk, and it is far easier to administer (one push vs a 1-hour infusion) - Rosen's Emergency Medicine, p. 1434-1435
Reteplase is now being considered by newer AHA/ASA guidance for eligible patients within 4.5h not undergoing thrombectomy, per recent society updates.

Time windows

  • 0-3 hours from clearly known symptom onset: strongest evidence base (NINDS trial); alteplase indicated in eligible patients.
  • 3-4.5 hours: extended window with additional exclusion criteria (age >80, NIHSS >25, combined history of stroke and diabetes, oral anticoagulant use regardless of INR are relative cautions in this extended window).
  • Unknown onset / "wake-up" stroke, up to ~24 hours: can be considered when advanced imaging (DWI-FLAIR mismatch or perfusion-core mismatch) shows salvageable tissue - supported by pooled trial data (Lancet 2020 meta-analysis cited in Goldman-Cecil Medicine).
  • Basilar artery occlusion may be treated up to 24 hours per 2024 ESO/ESMINT guidance even without advanced imaging in some protocols.

Key exclusion criteria (absolute/major relative contraindications)

  • Any evidence of intracranial hemorrhage on imaging
  • Active internal bleeding or known bleeding diathesis
  • Platelets <100,000/mm³, INR >1.7 or PT >15 sec if on warfarin, or therapeutic-level DOAC within the last 48h (unless specific reversal/levels checked)
  • Severe uncontrolled hypertension (>185/110 mmHg despite treatment)
  • Recent (within 3 months) ischemic stroke, serious head trauma, or intracranial/intraspinal surgery
  • Suspected subarachnoid hemorrhage
  • Blood glucose <50 mg/dL with symptoms resolving after correction
  • CT showing multilobar infarction involving more than one-third of the cerebral hemisphere
Notably, the FDA label was revised so that prior history of ICH, unruptured intracranial aneurysm/AVM, and intracranial neoplasm are no longer absolute contraindications - they are now relative, requiring individualized risk-benefit discussion (per USPharmacist/Activase labeling update).

Practical administration notes

  • Continuous BP monitoring, keep <180/105 mmHg during and after infusion
  • No antiplatelets or anticoagulants for 24 hours after alteplase/tenecteplase
  • Avoid arterial punctures, NG tubes, and indwelling catheters in the first 24 hours if possible
  • Repeat CT at 24 hours before starting any antithrombotic therapy
  • Watch for orolingual angioedema (can compromise airway) and symptomatic hemorrhagic transformation
  • IV thrombolysis and mechanical thrombectomy are not mutually exclusive - eligible large-vessel occlusion patients should receive both (bridging therapy) when thrombectomy is available.

Recent evidence worth flagging

A few recent systematic reviews/meta-analyses may refine practice beyond standard textbook coverage:
  • Safety outcomes network meta-analysis of IV thrombolytic agents (PMID: 41026449, 2026)
  • IV thrombolysis in patients on direct oral anticoagulants (PMID: 39831680, 2025) - relevant since DOAC use is a common real-world exclusion dilemma
  • IV thrombolysis in posterior circulation stroke (PMID: 38395096, 2024) - supports broader use of thrombolysis in posterior circulation strokes where the classic time-based criteria may be too restrictive
If you're managing an actual suspected case, the immediate priorities are: confirm last-known-well time, get a stat non-contrast CT, check glucose and coagulation status/platelets, and calculate weight-based dose while checking the exclusion list above - ideally with neurology involved in real time.
This is a shared conversation. Sign in to Orris to start your own chat.